Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer
NCT05747326Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and capecitabine in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free Survival at 1 year. Status: unknown.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05747326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747326.